Stephen Barri Heitner MD FACC, FASE

PubMed

• Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants.
  Neha Maharao, Donghong Xu, Tyrell J Simkins, Owen Bowles, Genzhou Liu
  Clinical and Translational Science. 2025-04-01
• 1 citations
  Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten.
  Donghong Xu, Justin D Lutz, Punag Divanji, Jianlin Li, Youcef Benattia
  Clinical Pharmacokinetics. 2025-03-01
• Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics.
  Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, Juan Pablo Costabel, Edileide de Barros Correia
  JACC. Heart Failure. 2025-02-01

Journal Articles

• Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History  
  Stephen Heitner, MD, JAMA Cardiology

Abstracts/Posters

• [Board 518] Long-Term Safety and Effectiveness of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients PIONEER-Open Label Extension Study (PIONE...
  Stephen Heitner, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/17/2019
• [Board 279] Implantable Cardioverter-Defibrillators For Children With Cardiac Conditions Associated With High Risk For Sudden Cardiac Death: A Cost-Effectiveness Analy...
  Stephen Heitner, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/16/2019
• [Board 561] Home AEDs For Children With Cardiac Conditions Associated With Intermediate Risk For Sudden Cardiac Death: A Cost-Effectiveness Analysis
  Stephen Heitner, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/16/2019

Lectures

• AG10 Consistently Stabilizes Transthyretin to a High Level in Both Wild Type and Mutant Amyloid Cardiomyopathy: Responder Analyses From a Phase 2 Clinical Trial 
  2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019